New combo therapy aims to save esophagus in cancer patients

NCT ID NCT05667298

Ongoing Disease control Sponsor: University of Manitoba Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study is testing whether a combination of endoscopic surgery, chemotherapy, radiation, and an immunotherapy drug (durvalumab) can safely treat early esophageal cancer without removing the esophagus. Eleven patients with stage T1b or T2 cancer who cannot or choose not to have esophagectomy are enrolled. The main goals are to see if the approach is feasible and safe, and to monitor side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Durvalumab (immunotherapy drug) plus chemoradiation
What this could lead to: If successful, this could offer a way to treat esophageal cancer without removing the esophagus, potentially preserving organ function and quality of life.
What could go wrong: This is a very early phase 1 trial with only 11 participants, so it is primarily testing safety and feasibility. The combination of treatments may cause serious side effects, and it is not yet known if it will effectively control the cancer long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

esophageal cancer Esophageal Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ESOPHAGEAL CANCER

Contacts and locations

Show contact details

Locations

CancerCare Manitoba

Winnipeg, Manitoba, R3E 0V9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.